News Releases

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company focused on developing first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will participate

TPST-1120 Late-breaking Poster Presentation at SITC Annual Meeting Second Poster Presentation Demonstrates that Dual Blockade of EP2 and EP4 PGE2 Receptors with TPST-1495 is an Optimal Approach for Drugging the Prostaglandin Pathway SOUTH SAN FRANCISCO, Calif., Nov.

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended

TPST-1495 also will be featured in a separate presentation SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms,

Dara Burdette, Ph.D., Tempest Senior Director of Discovery Research, to Chair “New Approaches to Solid Tumor Targeting” Session Nicholas DeVito, M.D, Duke University School of Medicine, to present TPST-1495 preclinical data SOUTH SAN FRANCISCO, Calif., Oct.

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Stephen R.

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June

President Tom Dubensky, Ph.D., to Share Expertise on Next Generation Immuno-Oncolgy Targets SOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted

TPST-1120 demonstrated monotherapy clinical benefit in patients with late-line advanced, poor-prognosis cancers where responses would be unexpected RECIST responses observed with TPST-1120 combined with anti-PD1 therapy in patients who previously progressed on anti-PD1/PDL1 therapy Potential

SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the

RECIST responses observed in IO-refractory patients and in IO-resistant indications 30% ORR in patients treated at the two highest TPST-1120 doses in combination with nivolumab (3/10); 20% ORR in all evaluable combination patients (3/15) 53% DCR in monotherapy patients (10/19) Responses observed in

Announced oral presentation of TPST-1120 Phase 1 monotherapy and combination therapy data at ASCO Presented positive preclinical data for TPST-1495 at AACR Presented positive preclinical data with proprietary small molecule TREX1 inhibitors at AACR SOUTH SAN FRANCISCO, Calif., May 13, 2022 (GLOBE

Oral presentation for TPST-1120 completed Phase 1 trial results Poster presentation for TPST-1495 trial in progress SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing therapeutics that combine both

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing novel therapeutics that combine both targeted and immune-mediated mechanisms, today announced a $15 million private investment in public equity

Anti-tumor data from systemic novel TREX1 inhibitors designed to activate the STING pathway selectively in tumors Additional data further supporting and differentiating TPST-1495, a clinical-stage dual EP2/4 prostaglandin receptor antagonist SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE

First clinical data presentation planned for ASCO: TPST-1120 Phase 1 monotherapy and combination dose escalation and optimization arms TPST-1120 randomized study in first-line HCC patients with partner Roche is ongoing, with initial data expected by YE22/early 2023 TPST-1495 Phase 1 monotherapy and

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the 32nd

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced two poster presentations at the 2022

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the 11th